logo
Plus   Neg
Share
Email

Catabasis Pharma's Phase 3 DMD Trial Exceeds Target Enrollment; Stock Up 5%

Shares of Catabasis Pharmaceuticals Inc. (CATB) are up over 5% in premarket trading on Tuesday, following the completion of enrollment in the Company's phase III trial of Edasalonexent in Duchenne muscular dystrophy.

The study, dubbed PolarisDMD, has exceeded the target enrollment of 125 boys, and has enrolled 130 boys ages 4 to 7 with any mutation type and who had not been on steroids for the past 6 months.

The Company expects to report top-line results from the phase III PolarisDMD trial in the fourth quarter of 2020, with NDA filing for Edasalonexent anticipated in 2021.

Duchenne Muscular Dystrophy, or DMD in short, is a rare genetic muscle-wasting disease caused by the absence of dystrophin, a protein necessary for muscle function. DMD usually affects boys, and its prevalence is roughly 1 in 3,500 boys worldwide.

PTC Therapeutics' Emflaza and Sarepta Therapeutics' Exondys 51 are the two FDA-approved drugs for DMD.

CATB closed Monday's trading at $5.40, up 1.89%. In Tuesday's premarket trading, the stock is up 5.56% at $5.70.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apotex Corp. recalled all lots of type 2 diabetes medication Metformin hydrochloride in the form of oral film-coated tablets for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine (NDMA), above levels of the Acceptable Daily Intake Limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement. Groupe Renault plans to cut about 14,600 jobs across the world and lower its production capacity. The plan includes almost 4,600 jobs reduction in France, through voluntary retirement and retraining. Amazon said it will convert 125,000 of the 175,000 temporary workers it hired in March amid the coronavirus pandemic, to permanent full-time employees in June. The e-commerce giant had hired the temporary employees in March to meet strong consumer demand amid the lockdown. The job openings were in Amazon's fulfillment centers and its delivery network.
Follow RTT